Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones - Annexon Biosciences




Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

May 13, 2024

Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024

Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024; Potential to be the First Targeted Treatment for GBS

New Phase 2 Data Showing Neuroprotection of Vision and Vision-Associated Structures by ANX007 in Geographic Atrophy (GA) Presented at ARVO 2024; Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in GA Expected in mid-2024

Clinical Proof of Concept (POC) Data for ANX1502, an Oral Classical Pathway Inhibitor for Chronic Autoimmune Conditions, on Track for Second Half of 2024

Robust Balance Sheet with Cash, Cash Equivalents, and Short-term Investments of Approximately $264.9 Million as of March 31, 2024, and Anticipated Runway into mid-2026

BRISBANE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today highlighted portfolio progress and reported first quarter 2024 financial results.

“We are pleased with the increasingly robust opportunities across our flagship programs to drive significant value, including the late-stage potential of ANX005 to be the first targeted treatment for GBS with upcoming pivotal Phase 3 data, the potential of ANX007 to change the GA treatment landscape following first-in-class vision and anatomical neuroprotection data from the Phase 2 ARCHER study, and an upcoming proof-of-concept trial with the first and only oral compound targeting classical complement mediated diseases,” said Douglas Love, president and chief executive officer of Annexon. “2024 is an exciting and potentially transformative year for Annexon, with multiple value-creating catalysts culminating from a decade of research in developing treatments designed to stop harmful classical complement pathway inflammation where it starts.”

Mr. Love continued, “Our foundational research and deep knowledge of the classical complement pathway has identified several diseases and patient populations uniquely impacted by classical complement activity and translated these learnings into the development of multiple drug candidates and formulations tailored for diseases of the body, brain and eye. With our strong cash position and the compelling functional data generated across our pipeline to date, we are well-positioned to achieve our mission of bringing our first-in-kind therapies to millions of patients and families impacted by devastating classical complement diseases.”

Recent Clinical Program Updates

Flagship Programs

ANX005 in GBS: First-in-class monoclonal antibody designed to block C1q and the entire classical complement pathway in both the body and the brain.

ANX007 in GA: First-in-class, non-pegylated antigen-binding fragment (Fab) designed to block C1q and activation of the classical complement cascade locally in the eye with an intravitreal formulation.

ANX1502 for Autoimmune Conditions: First-in-class oral small molecule inhibitor of the classical complement pathway designed to target chronic autoimmune diseases.

Key 2024 Anticipated Milestones for Flagship Programs

First Quarter 2024 Financial Results

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Annexon’s novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic candidates are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. With proof-of concept data in Guillain-Barré syndrome, Huntington’s disease and geographic atrophy, Annexon is rigorously advancing its mid-to late-stage clinical trials to bring new potential treatments to patients as quickly as possible. To learn more visit

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the timing of completion of Phase 3 trial of ANX005 in patients with GBS; the potential therapeutic benefit of ANX005, if approved, compared to existing therapies; anticipated timing of the completion of a RWE comparability study and BLA submission for ANX005; the potential therapeutic benefit of ANX007; timing of initiation of the ARCHER II and ARROW trials; ANX007’s distinct potential neuroprotective mechanism of action and potential to provide protection from vision loss; timing of proof-of-concept data for ANX1502; continued development of ANX007 and ANX1502; anticipated cash runway into mid-2026; the potential benefits from treatment with anti-C1q therapy; and continuing advancement of the company’s portfolio. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the ongoing off-treatment follow-up portion of the ARCHER trial and final results from the ARCHER trial; the company’s history of net operating losses; the company’s ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company’s product candidates; the effects of public health crises on the company’s clinical programs and business operations; the company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the company’s product candidates; the company’s reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company’s ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled “Risk Factors” contained in the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company’s other filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Joyce Allaire
LifeSci Advisors

Media Contact:

Sheryl Seapy
Real Chemistry

Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
    Three Months Ended
March 31,
    2024     2023  
Operating expenses:            
Research and development (1)   $ 20,963     $ 32,345  
General and administrative (1)     7,609       8,897  
Total operating expenses     28,572       41,242  
Loss from operations     (28,572 )     (41,242 )
Interest and other income, net     3,396       2,566  
Net loss   $ (25,176 )   $ (38,676 )
Net loss per share, basic and diluted   $ (0.21 )   $ (0.52 )
Weighted-average shares used in computing net loss per share,
basic and diluted
    122,673,202       73,855,642  


(1) Includes the following stock-based compensation expense:            
Research and development   $ 2,282     $ 2,251  
General and administrative   $ 2,378     $ 2,356  

Condensed Consolidated Balance Sheets
(in thousands)
    March 31,     December 31,  
    2024     2023  
Current assets:            
Cash and cash equivalents   $ 151,941     $ 225,110  
Short-term investments     113,007       34,606  
Prepaid expenses and other current assets     5,792       4,144  
Total current assets     270,740       263,860  
Restricted cash     1,032       1,032  
Property and equipment, net     14,235       14,773  
Operating lease right-of-use assets     17,701       18,009  
Other non-current assets     361        
Total assets   $ 304,069     $ 297,674  
Liabilities and Stockholders' Equity            
Current liabilities:            
Accounts payable   $ 3,972     $ 5,487  
Accrued liabilities     6,857       10,235  
Operating lease liabilities, current     2,254       2,165  
Other current liabilities     50       41  
Total current liabilities     13,133       17,928  
Operating lease liabilities, non-current     28,531       29,190  
Total liabilities     41,664       47,118  
Stockholders’ equity:            
Common stock     90       78  
Additional paid-in capital     860,092       823,029  
Accumulated other comprehensive loss     (102 )     (52 )
Accumulated deficit     (597,675 )     (572,499 )
Total stockholders' equity     262,405       250,556  
Total liabilities and stockholders’ equity   $ 304,069     $ 297,674  

« back to news page